Lucid Group Inc vs Sanofi SA — how do they compare? Lucid Group Inc trades at $6.5 (market cap $2.64B), while Sanofi SA trades at $43.59 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 39.5× Lucid Group Inc's market cap, and Sanofi SA pays a 5.55% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| LCID | SNY | |
|---|---|---|
Market Cap | $2.64B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.77 | $52.34 |
52-Week Low | $4.62 | $41.33 |
Enterprise Value | $5.54B | $124.19B |
Dividend Yield | — | 5.55% |
Signals from Pluang's Aura AI — not financial advice
Lucid (LCID) trades at $6.495, down 1.74% on the day, amid a bearish technical signal and weak fundamentals. The company reported a Q2 2026 EPS miss of -$3.30 versus -$2.41 expected, with revenue growth overshadowed by negative gross and net income margins. Recent news highlights an operational reset targeting $1.4 billion in cash savings and a delayed EV launch, reflecting ongoing challenges in the competitive EV market.
The outlook remains high-risk due to persistent losses and cash burn, though analyst consensus suggests modest upside to a $10.50 price target. Investment opportunities hinge on successful cost-cutting and robotaxi initiatives, while risks include execution missteps and intense competition. With 66.7% of analysts rating Hold, cautious optimism is tempered by financial instability.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →